Mesenchymal stem cell and derived exosome as small RNA carrier and Immunomodulator to improve islet transplantation

Di Wen, Yang Peng, Di Liu, Yossi Weizmann, Ram I Mahato

Research output: Contribution to journalArticle

37 Scopus citations


Human bone marrow mesenchymal stem cells (hBMSCs) and their exosomes can suppress immune reaction and deliver small RNAs. Thus, they may improve islet transplantation by delivering small RNAs for promoting islet function and inhibiting immune rejection. Here, we proposed an hBMSC and its exosome-based therapy to overcome immune rejection and poor islet function, both of which hinder the success of islet transplantation. We found overexpressed siFas and anti-miR-375 in plasmid encoding shFas and anti-miR-375 transfected hBMSC-derived exosomes, which silenced Fas and miR-375 of human islets and improved their viability and function against inflammatory cytokines. This plasmid transfected hBMSCs downregulated Fas and miR-375 of human islets in a humanized NOD scid gamma (NSG) mouse model, whose immune reaction was inhibited by injecting hBMSC and peripheral blood mononuclear cell (PBMC) co-cultured exosomes. These exosomes suppressed immune reaction by inhibiting PBMC proliferation and enhancing regulatory T cell (Treg) function. Collectively, our studies elucidated the mechanisms of RNA delivery from hBMSCs to human islets and the immunosuppressive effect of hBMSC and peripheral blood mononuclear cell co-cultured exosomes for improving islet transplantation.

Original languageEnglish (US)
Pages (from-to)166-175
Number of pages10
JournalJournal of Controlled Release
StatePublished - Sep 28 2016



  • Exosome
  • Immunotherapy
  • Islet transplantation
  • Type 1 diabetes

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this